Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

The MDM2 oncoprotein binds to p53 and abrogates p53-mediated G1 arrest and apoptosis. We show that MDM2 over-expression accelerates cell cycle progression of RPMI2650 cells by overcoming the ...

with MET overexpression: Results from a phase Ib/II trial. Percentage change in MET, TROP2, HER2, B7-H4, and MDM2 following previous treatment.

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced ...

Scientists have recently shed some light on exactly why elephants, one of the biggest animals on the planet, paradoxically ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs ...

These patients typically display (1) abnormal p53 protein expression in bone marrow cells by immunohistochemistry; (2) upstream p53 signaling aberrations (including PI3K, RAS, WNT, NF-kB pathways and ...

Western blot assays were performed to identify the presence of p53, phospho-p53, and murine double minute 2 (MDM2) isoforms in plasma samples. Densitometric analysis was used to determine the ...

Pathos also took ownership of the phase 3-stage MDM2 inhibitor milademetan as part of its acquisition of Rain Oncology in December 2023. However, Pathos hasn’t name-checked the failed ...

In oncology, she highlighted MDM2-p53 antagonist brigimadlin, which has advanced into a pivotal trial for dedifferentiated liposarcoma, a rare cancer with limited treatment options so far ...

p300 acetylates and activates the tumor suppressor p53 after DNA damage. Here, we show that MDM2, a negative-feedback regulator of p53, inhibited p300-mediated p53 acetylation by complexing with these ...